Resveratrol decreases the insoluble Aβ1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats

Neuroscience

Volumn 310, Issue , 2015, Pages 641-649

  Zhao, H F ^a   Li, N ^a   Wang, Q ^a   Cheng, X J ^a   Li, X M ^b   Liu, T T ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b Center for Disease Control and Prevention in Shanxi Province   (China)

Author keywords

Beta amyloid peptide 1 42; Claudin 5; Matrix metalloprotein 9; Nuclear factor kappaB; Receptor for advanced glycation endproducts; Resveratrol

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN[1-42]; CLAUDIN 5; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RESVERATROL; TRANSCRIPTION FACTOR RELA; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTIOXIDANT; CLDN5 PROTEIN, RAT; GALACTOSE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE FRAGMENT; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HIPPOCAMPUS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; OVARIECTOMY; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; CLAUDIN-5; DISEASE MODELS, ANIMAL; FEMALE; GALACTOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HIPPOCAMPUS; MATRIX METALLOPROTEINASE 9; OVARIECTOMY; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; STILBENES; TRANSCRIPTION FACTOR RELA;

EID: 84944878466     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.10.006     Document Type: Article

References (63)

1. Agyare E.K., Leonard S.R., Curran G.L., Yu C.C., Lowe V.J., Paravastu A.K., Poduslo J.F., Kandimalla K.K. Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-beta proteins in the cerebral vasculature. Mol Pharm 2013, 10:1557-1565.
2. Annabi B., Lord-Dufour S., Vezina A., Beliveau R. Resveratrol targeting of carcinogen-induced brain endothelial cell inflammation biomarkers MMP-9 and COX-2 is Sirt1-independent. Drug Target Insights 2012, 6:1-11.
3. Aqeel Y., Iqbal J., Siddiqui R., Gilani A.H., Khan N.A. Anti-acanthamoebic properties of resveratrol and demethoxycurcumin. Exp Parasitol 2012, 132:519-523.
4. Bellaver B., Souza D.G., Souza D.O., Quincozes-Santos A. Resveratrol increases antioxidant defenses and decreases proinflammatory cytokines in hippocampal astrocyte cultures from newborn, adult and aged Wistar rats. Toxicol In Vitro 2014, 28:479-484.
5. Birch A.M., Katsouri L., Sastre M. Modulation of inflammation in transgenic models of Alzheimer's disease. J Neuroinflammation 2014, 11:25.
6. Bitel C.L., Kasinathan C., Kaswala R.H., Klein W.L., Frederikse P.H. Amyloid-beta and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J Alzheimers Dis 2012, 32:291-305.
7. Bradshaw E.M., Chibnik L.B., Keenan B.T., Ottoboni L., Raj T., Tang A., Rosenkrantz L.L., Imboywa S., Lee M., Von Korff A., Alzheimer Disease Neuroimaging I., Morris M.C., Evans D.A., Johnson K., Sperling R.A., Schneider J.A., Bennett D.A., De Jager P.L. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 2013, 16:848-850.
8. Castellano J., Badimon L., Llorente-Cortes V. Amyloid-beta increases metallo- and cysteine protease activities in human macrophages. J Vasc Res 2014, 51:58-67.
9. Cecchelli R., Aday S., Sevin E., Almeida C., Culot M., Dehouck L., Coisne C., Engelhardt B., Dehouck M.P., Ferreira L. A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells. PLoS One 2014, 9:e99733.
10. Cong X., Li Y., Lu N., Dai Y., Zhang H., Zhao X., Liu Y. Resveratrol attenuates the inflammatory reaction induced by ischemia/reperfusion in the rat heart. Mol Med Rep 2014, 9:2528-2532.
11. Deane R., Singh I., Sagare A.P., Bell R.D., Ross N.T., LaRue B., Love R., Perry S., Paquette N., Deane R.J., Thiyagarajan M., Zarcone T., Fritz G., Friedman A.E., Miller B.L., Zlokovic B.V. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Investig 2012, 122:1377-1392.
12. Ejlertsen B., Jensen M.B., Mouridsen H.T. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol 2014, 53:174-185. Danish Breast Cancer Cooperative G.
13. Gomes G.M., Dalmolin G.D., Bar J., Karpova A., Mello C.F., Kreutz M.R., Rubin M.A. Inhibition of the polyamine system counteracts beta-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors. PLoS One 2014, 9:e99184.
14. Gweon E.J., Kim S.J. Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. Oncol Rep 2014, 32:71-78.
15. Gu R., Jia W., Zeng Y., Rao N., Hu Y., Li S., Wu J., Jin L., Chen L., Long M., Chen K., Chen L., Xiao Q., Wu M., Song E., Su F. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. BMC Cancer 2012, 12:161.
16. Han S.H., Kim Y.H., Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011, 31:91-97.
17. Henderson V.W. Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 2014, 142:99-106.
18. Holmes C., Butchart J. Systemic inflammation and Alzheimer's disease. Biochem Soc Trans 2011, 39:898-901.
19. Hua X., Lei M., Zhang Y., Ding J., Han Q., Hu G., Xiao M. Long-term d-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease. Life Sci 2007, 80:1897-1905.
20. Ishrat T., Sayeed I., Atif F., Hua F., Stein D.G. Progesterone and allopregnanolone attenuate blood-brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. Exp Neurol 2010, 226:183-190.
21. Jamshed N., Ozair F.F., Aggarwal P., Ekka M. Alzheimer disease in post-menopausal women: Intervene in the critical window period. J Midlife Health 2014, 5:38-40.
22. Jia W., Lu R., Martin T.A., Jiang W.G. The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (review). Mol Med Rep 2014, 9:779-785.
23. Jin L., Wu W.H., Li Q.Y., Zhao Y.F., Li Y.M. Copper inducing Abeta42 rather than Abeta40 nanoscale oligomer formation is the key process for Abeta neurotoxicity. Nanoscale 2011, 3:4746-4751.
24. Jing Y.H., Chen K.H., Yang S.H., Kuo P.C., Chen J.K. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab Res Rev 2010, 26:212-222.
25. Kim Y.H., Kim Y.S., Roh G.S., Choi W.S., Cho G.J. Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol 2012, 90:e31-37.
26. Knobloch J., Wahl C., Feldmann M., Jungck D., Strauch J., Stoelben E., Koch A. Resveratrol attenuates the release of inflammatory cytokines from human bronchial smooth muscle cells exposed to lipoteichoic acid in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol 2014, 114:202-209.
27. Lan Y.L., Zhao J., Li S. Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease. J Alzheimers Dis 2014.
28. Liu L., Su Y., Yang W., Xiao M., Gao J., Hu G. Disruption of neuronal-glial-vascular units in the hippocampus of ovariectomized mice injected with d-galactose. Neuroscience 2010, 169:596-608.
29. Lopez-Grueso R., Gambini J., Abdelaziz K.M., Monleon D., Diaz A., El Alami M., Bonet-Costa V., Borras C., Vina J. Early, but not late onset estrogen replacement therapy prevents oxidative stress and metabolic alterations caused by ovariectomy. Antioxid Redox Signal 2014, 20:236-246.
30. Mackic J.B., Bading J., Ghiso J., Walker L., Wisniewski T., Frangione B., Zlokovic B.V. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol 2002, 38:303-313.
31. Malmsten L., Vijayaraghavan S., Hovatta O., Marutle A., Darreh-Shori T. Fibrillar beta-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation. J Cell Mol Med 2014.
32. Mann G.E., Zlokovic B.V., Yudilevich D.L. Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon. Biochim Biophys Acta 1985, 819:241-248.
33. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985, 82:4245-4249.
34. Mauris J., Woodward A.M., Cao Z., Panjwani N., Argueso P. Molecular basis for MMP9 induction and disruption of epithelial cell-cell contacts by galectin-3. J Cell Sci 2014, 127:3141-3148.
35. Mielke M.M., Vemuri P., Rocca W.A. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol 2014, 6:37-48.
36. Montagne A., Barnes S.R., Sweeney M.D., Halliday M.R., Sagare A.P., Zhao Z., Toga A.W., Jacobs R.E., Liu C.Y., Amezcua L., Harrington M.G., Chui H.C., Law M., Zlokovic B.V. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015, 85:296-302.
37. Murray M.M., Bernstein S.L., Nyugen V., Condron M.M., Teplow D.B., Bowers M.T. Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization. J Am Chem Soc 2009, 131:6316-6317.
38. Pallas M., Ortuno-Sahagun D., Benito-Andres P., Ponce-Regalado M.D., Rojas-Mayorquin A.E. Resveratrol in epilepsy: preventive or treatment opportunities?. Front Biosci 2014, 19:1057-1064.
39. Paris D., Patel N., Quadros A., Linan M., Bakshi P., Ait-Ghezala G., Mullan M. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett 2007, 415:11-16.
40. Ravindran J., Agrawal M., Gupta N., Rao P.V. Alteration of blood brain barrier permeability by T-2 toxin: role of MMP-9 and inflammatory cytokines. Toxicology 2011, 280:44-52.
41. Saha A., Sarkar C., Singh S.P., Zhang Z., Munasinghe J., Peng S., Chandra G., Kong E., Mukherjee A.B. The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol. Hum Mol Genet 2012, 21:2233-2244.
42. Saleh M.C., Connell B.J., Saleh T.M. Resveratrol induced neuroprotection is mediated via both estrogen receptor subtypes, ER(alpha) and ER(beta). Neurosci Lett 2013, 548:217-221.
43. Serrano-Pozo A., Muzikansky A., Gomez-Isla T., Growdon J.H., Betensky R.A., Frosch M.P., Hyman B.T. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 2013, 72:462-471.
44. Shao A.W., Wu H.J., Chen S., Ammar A.B., Zhang J.M., Hong Y. Resveratrol attenuates early brain injury after subarachnoid hemorrhage through inhibition of NF-kappaB-dependent inflammatory/MMP-9 pathway. CNS Neurosci Ther 2014, 20:182-185.
45. Soylemez S., Gurdal H., Sepici A., Akar F. The effect of long-term resveratrol treatment on relaxation to estrogen in aortae from male and female rats: role of nitric oxide and superoxide. Vascul Pharmacol 2008, 49:97-105.
46. Su Y., Sun H., Fang J., Hu G., Xiao M. Brain mitochondrial dysfunction in ovariectomized mice injected with d-galactose. Neurochem Res 2010, 35:399-404.
47. Sun Y., Lee H.J., Yang S.C., Chen T.F., Lin K.N., Lin C.C., Wang P.N., Tang L.Y., Chiu M.J. A nationwide survey of mild cognitive impairment and dementia, including very mild dementia, in Taiwan. PLoS One 2014, 9:e100303.
48. Takechi R., Pallebage-Gamarallage M.M., Lam V., Giles C., Mamo J.C. Nutraceutical agents with anti-inflammatory properties prevent dietary saturated-fat induced disturbances in blood-brain barrier function in wild-type mice. J Neuroinflammation 2013, 10:73.
49. Tasci A., Bilgili H., Altunay H., Gecit M.R., Keskin D. Biomechanical and histological outcome of combined raloxifene-estrogen therapy on skeletal and reproductive tissues. Eur J Pharmacol 2010, 627:354-361.
50. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., Janle E.M., Lobo J., Ferruzzi M.G., Davies P., Marambaud P. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010, 285:9100-9113.
51. Wang L., Kittaka M., Sun N., Schreiber S.S., Zlokovic B.V. Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats. J Cereb Blood Flow Metab 1997, 17:136-146.
52. Wang Q., Ishikawa T., Michiue T., Zhu B.L., Guan D.W., Maeda H. Molecular pathology of brain matrix metalloproteases, claudin5, and aquaporins in forensic autopsy cases with special regard to methamphetamine intoxication. Int J Legal Med 2014, 128:469-474.
53. Wei H., Wang S., Zhen L., Yang Q., Wu Z., Lei X., Lv J., Xiong L., Xue R. Resveratrol attenuates the blood-brain barrier dysfunction by regulation of the MMP-9/TIMP-1 balance after cerebral ischemia reperfusion in rats. J Mol Neurosci 2015, 55:872-879.
54. Yang S.J., Lim Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metab Clin Exp 2014, 63:693-701.
55. Zettersten C., Co M., Wende S., Turner C., Nyholm L., Sjoberg P.J. Identification and characterization of polyphenolic antioxidants using on-line liquid chromatography, electrochemistry, and electrospray ionization tandem mass spectrometry. Anal Chem 2009, 81:8968-8977.
56. Zhang X., Wang J., Xing Y., Gong L., Li H., Wu Z., Li Y., Wang J., Wang Y., Dong L., Li S. Effects of ginsenoside Rg1 or 17beta-estradiol on a cognitively impaired, ovariectomized rat model of Alzheimer's disease. Neuroscience 2012, 220:191-200.
57. Zhang Y., Wei G., Di Z., Zhao Q. MiR-339-5p inhibits alcohol-induced brain inflammation through regulating NF-kappaB pathway. Biochem Biophys Res Commun 2014, 452:450-456.
58. Zhao H., Niu Q., Li X., Liu T., Xu Y., Han H., Wang W., Fan N., Tian Q., Zhang H., Wang Z. Long-term resveratrol consumption protects ovariectomized rats chronically treated with d-galactose from developing memory decline without effects on the uterus. Brain Res 2012, 1467:67-80.
59. Zhou C., Steplowski T.A., Dickens H.K., Malloy K.M., Gehrig P.A., Boggess J.F., Bae-Jump V.L. Estrogen induction of telomerase activity through regulation of the mitogen-activated protein kinase (MAPK) dependent pathway in human endometrial cancer cells. PLoS One 2013, 8:e55730.
60. Zlokovic B.V. Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res 1995, 12:1395-1406.
61. Zlokovic B.V. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 2008, 5:409-414.
62. Zlokovic B.V., Begley D.J., Chain-Eliash D.G. Blood-brain barrier permeability to leucine-enkephalin, d-alanine2-d-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Res 1985, 336:125-132.
63. Zlokovic B.V., Lipovac M.N., Begley D.J., Davson H., Rakic L. Transport of leucine-enkephalin across the blood-brain barrier in the perfused guinea pig brain. J Neurochem 1987, 49:310-315.